Rhythm and Camurus Announce License Agreement for Extended

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Jan 5, 2016 at 2:15 AM

Rhythm and Camurus Announce License Agreement for Extended Release FluidCrystal Setmelanotide

Boston and Lund, Sweden — 5 January 2016 — Rhythm and Camurus announced today a license agreement for the use of Camurus’ drug delivery technology, FluidCrystal®, to formulate setmelanotide (RM-493), Rhythm’s novel melanocortin -4 receptor (MC4R) agonist. Under the terms of the agreement, Camurus has granted Rhythm a worldwide license to the FluidCrystal technology to formulate setmelanotide and to develop, manufacture, and commercialize this new formulation that has the potential for once-weekly dosing, administered as a subcutaneous injection. Rhythm plans to initiate a Phase I clinical trial with the setmelanotide FluidCrystal formulation after completing GMP manufacturing. “We have developed a setmelanotide formulation with Camurus with an impressive sustained-duration profile,” said Bart Henderson, President of Rhythm. “We believe this new formulation will provide a significant benefit to patients, improving compliance and ease of use with once-weekly dosing.” “The partnership with Rhythm follows the formulation development and preclinical assessment of this compelling drug candidate based on our FluidCrystal Injection depot technology,” said Fredrik Tiberg, President and CEO of Camurus. “Rhythm’s setmelanotide represents a novel approach to treating patients suffering from life-threatening obesity due to these rare and serious genetic disorders.” The license granted to Rhythm is specific to the FluidCrystal technology incorporating setmelanotide. The formulation has been developed in a collaboration between the companies. Under the terms of the license agreement, Rhythm is responsible for manufacturing, development, and commercialization of the setmelanotide FluidCrystal formulation worldwide. Camurus is eligible to receive an upfront payment and progressive payments of approximately $65 million, of which the majority are sales milestones. In addition, Camurus is eligible to receive tiered, mid to mid-high, single digit royalties on future sales of the product. About Setmelanotide (RM-493) Setmelanotide is a potent, first-in-class MC4R agonist in development for the treatment of obesity caused by genetic deficiencies in the MC4 pathway, a key pathway in humans that regulates energy expenditure, homeostasis, and appetite. The critical role of the MC4 pathway in weight regulation was validated with the discovery that single genetic defects along this pathway result in early-onset and severe obesity. A Phase 2 setmelanotide trial is ongoing for the treatment of Prader-Willi syndrome (PWS), a rare genetic disorder that causes life -threatening obesity. Recent scientific evidence implicates defects in the MC4 pathway as the likely cause of the weight and appetite abnormalities in PWS. A second Phase 2 trial is ongoing for the treatment of pro-opiomelanocortin (POMC) deficiency obesity, a very rare, life-threatening genetic disorder of the MC4 pathway associated with unrelenting appetite and obesity. About FluidCrystal Injection Depot The FluidCrystal Injection depot delivers therapeutic levels of drug substance over extended periods — tunable from days to months — from a single injection. While traditional depot therapeutics comprise complicated microsphere technology, Camurus' depot offers a liquid solution that transforms into a controlled release liquid crystal gel matrix in situ on contact with minute quantities of aqueous fluid at site of injection. The FluidCrystal delivery system overcomes traditional side effects associated with high initial drug release on injection (drug burst) and poor drug stability by effectively encapsulating the drug compound in the nanopores of the depot matrix throughout the entire process from injection until final degradation. This, together with the ready-to-use product design, makes the system highly suitable for sustained parenteral delivery of peptides and proteins. FluidCrystal is a registered trademark of Camurus AB. About Rhythm (www.rhythmtx.com) Rhythm is a biopharmaceutical company focused on developing peptide therapeutics for the treatment of rare genetic deficiencies that result in life-threatening metabolic disorders. Rhythm’s lead peptide product candidate is setmelanotide, a first-in-class melanocortin 4 receptor (MC4R) agonist for the treatment of rare genetic disorders of obesity. The company is based in Boston, Massachusetts. About Camurus Camurus is a Swedish research-based pharmaceutical company committed to developing and commercialising innovative and differentiated medicines for the treatment of severe and chronic conditions. New drug products with best-in-class potential are conceived based on the proprietary FluidCrystal® drug delivery technologies and an extensive R&D expertise. Camurus’ clinical pipeline includes products for treatment of cancer, endocrine diseases, pain and addiction, developed in-house and in collaboration with international pharmaceutical companies. The company’s shares are listed on Nasdaq Stockholm under the ticker “CAMX”. For more information, visit www.camurus.com. Media Contacts Camurus Fredrik Tiberg, President & CEO Tel: +46 (0)46 286 46 92 Rein Piir, VP Investor Relations Tel. +46 (0)70 853 72 92 ir@camurus.com Rhythm Bart Henderson, President Tel.: +1-857-264-4281 bhenderson@rhythmtx.com The information in this press release is disclosed by Camurus AB in accordance with the Swedish Securities Markets Act and/or the Swedish Financial Instruments Trading Act. The information was submitted for publication at 08.00 a.m. CET on 5 January 2016.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

BULL Faces Class Action After Regulatory Fines

Webull's Financial Quake Shakes Investors You don't expect to wake up to news of a stock in freefall, but here we are with Webull (NASDAQ:BULL) cratering after some rough compliance problems came to light. On November 5, 2026, Webull's stock tumbled nearly 11% thanks to FINRA slapping them with a $4.2 million fine for failing to keep their anti-money laundering (AML) and...

GTEC Faces Nasdaq Bid Price Compliance Challenge

Greenland Technologies in a Tight Spot Man, stocks can be as unpredictable as a cat on a hot tin roof, and Greenland Technologies Holding Corporation (Nasdaq: GTEC) just got a cold splash of reality from Nasdaq. On November 10, 2026, they were handed a Notification Letter that ain’t exactly a love note. Their shares slipped below the one-buck hurdle, and Nasdaq isn’t...

U-wifi Gains Charlie Vogt: Key Steps in 5G Expansion

Charlie Vogt Joins U-wifi: A Broadband Game Changer? There's a new player in town shaking things up, and he's no rookie. Charlie Vogt, five-time technology CEO and Managing Director at Bowen, is hopping onto U-wifi's board of directors. This isn't just about another corporate announcement; it's like adding a veteran quarterback to your expansion team. Vogt’s pedigree in...

Partner Joins Yardi ICN, Boosting Data Quality for Clients

Strategic Alliances in Real Estate Data When Partner Engineering and Science, Inc. says they're hooking up with the Yardi Independent Consultant Network (ICN), that's not just some boardroom handshake. It's a play that could shake up data services in the real estate game. Look, there's plenty of chatter about digitizing property management, but without killer data, those...

Choosing Screen-Free Outdoor Gifts: besrey's Top Picks

The Art of Choosing Outdoor Gifts for Kids Christmas time, my friends, isn't just about plastic gimmicks and gadgets vying for kids' attention. Nope, it's about making thoughtful decisions that blend discovery, movement, and a little peace of mind for parents. This time around, besrey's got the scoop on screen-free gifts that might just do the trick—helping kids explore...

SAHZU Hospital Earns GHA Distinction for Travel Care

A New Benchmark in International Patient Experience When a hospital sets the standard for treating foreign patients like family, it deserves recognition. That's exactly what's happened at The Second Affiliated Hospital Zhejiang University School of Medicine (SAHZU), which just snagged an impressive accolade from Global Healthcare Accreditation (GHA). For anyone keeping...

Cemig and Huawei's Bold Network Leap: Power Up

By Ryan Hughes Updated Nov 13, 2026 Category News Views 100

Taking the Leap in Brazil's Power Grid In Brazil, energy distribution's a whole different beast, and boy, is it complicated! Cemig found out the hard way that relying on public networks was a risky bet. Consistently bad. With a measly 50% coverage in Brazil's vast lands, you're looking at a communications nightmare, especially in the back of beyond where grid faults could...

Revolutionary Sports Ball Backpack: A Game Changer?

Backpacks Reinvented by a Clever Mom Ever been caught in the whirlwind of juggling kids, sports gear, and school supplies? Well, one stay-at-home mom from Poway, California found herself in just such a predicament. She turned this everyday chaos into a creative solution by designing a unique Sports Ball Backpack. The idea came to her while managing a toddler, a newborn,...

DEEPBLUE's Panelized Systems Target Low-Rise Markets

Changing the Game in Low-Rise Construction Been around the block a few times and seen all sorts of hype in this industry, but what DEEPBLUE SMARTHOUSE is pushing sounds more like evolution than revolution for low-rise builds. They're leaning into this panelized building system like a boxer on the ropes—that's their strategy to keep things steady and predictable. The...

DraftKings Shares Tumble, Investors Grapple with Losses

DraftKings' Bold Moves Hit Investor Pockets Hard It ain't every day you see a company gamble nearly $700 million and come out with egg on its face. Yet, that's what DraftKings (NASDAQ: DKNG) seems to have done, and now it's shareholders who might be left holding the bag. On November 6, 2026, when DraftKings admitted it was doubling down on its Predictions business...